Haleon plc (NYSE:HLN) Holdings Lifted by Pitcairn Co.

Pitcairn Co. boosted its holdings in shares of Haleon plc (NYSE:HLN) by 10.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 275,848 shares of the company’s stock after buying an additional 25,661 shares during the period. Pitcairn Co.’s holdings in Haleon were worth $2,632,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of the business. National Bank of Canada FI lifted its position in shares of Haleon by 195.8% in the fourth quarter. National Bank of Canada FI now owns 13,992 shares of the company’s stock worth $133,000 after purchasing an additional 9,262 shares in the last quarter. HighPoint Advisor Group LLC grew its position in Haleon by 6.2% during the fourth quarter. HighPoint Advisor Group LLC now owns 37,768 shares of the company’s stock valued at $372,000 after purchasing an additional 2,213 shares in the last quarter. Alliancebernstein L.P. increased its stake in Haleon by 28.1% in the 4th quarter. Alliancebernstein L.P. now owns 51,678 shares of the company’s stock valued at $493,000 after buying an additional 11,341 shares during the period. Wellington Management Group LLP lifted its position in Haleon by 67.5% in the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company’s stock worth $146,232,000 after buying an additional 6,175,835 shares in the last quarter. Finally, O Shaughnessy Asset Management LLC boosted its stake in shares of Haleon by 141.3% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 354,436 shares of the company’s stock valued at $3,381,000 after buying an additional 207,577 shares during the period. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Price Performance

Shares of NYSE:HLN opened at $10.16 on Thursday. The stock has a market capitalization of $46.00 billion, a P/E ratio of 29.88, a P/E/G ratio of 2.82 and a beta of 0.25. The business has a 50-day moving average of $10.00 and a two-hundred day moving average of $9.87. Haleon plc has a fifty-two week low of $7.99 and a fifty-two week high of $10.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.

Haleon (NYSE:HLN) last posted its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.38 billion. Haleon had a net margin of 10.85% and a return on equity of 14.76%. On average, equities research analysts predict that Haleon plc will post 0.43 EPS for the current fiscal year.

Haleon Increases Dividend

The firm also recently declared a — dividend, which will be paid on Thursday, June 5th. Shareholders of record on Friday, April 25th will be given a $0.1166 dividend. This is an increase from Haleon’s previous — dividend of $0.05. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, April 25th. Haleon’s payout ratio is currently 58.97%.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on HLN. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th. HSBC reaffirmed a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Hsbc Global Res cut Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Finally, Sanford C. Bernstein lowered shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Six research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.